Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 17/20 | 0.50 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2270517 | 0.82 | JAK2 (0.47) | TLR7 | |
| SCHEMBL13608332 | 0.79 | JAK2 (0.46) | TLR7 | |
| SCHEMBL12371690 | 0.77 | BIRC2 (0.42) | TLR7 | |
| SCHEMBL13608131 | 0.77 | BRD4 (0.41) | TLR7TRAP1HSP90AA1HSP90B1 | |
| SCHEMBL12371651 | 0.77 | JAK2 (0.45) | TLR7 | |
| SCHEMBL13608238 | 0.74 | JAK2 (0.45) | — | |
| SCHEMBL13608336 | 0.74 | PIK3CD (0.42) | TLR7 | |
| SCHEMBL13620380 | 0.74 | JAK2 (0.47) | TLR7 | |
| SCHEMBL12371659 | 0.72 | TLR7 (0.40) | TLR7TRAP1HSP90AA1HSP90B1 | |
| SCHEMBL12371654 | 0.71 | JAK2 (0.39) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | TLR7 3960/4885TRAP1 2493/4885HSP90AA1 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.